{
    "relation": [
        [
            "",
            "Everolimus",
            "Placebo"
        ],
        [
            "Description",
            "Study drug was given by continuous oral daily dosing of two 5 mg tablets.",
            "Placebo was given by continuous oral daily dosing of two 5 mg tablets."
        ]
    ],
    "pageTitle": "Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00790400?sect=X025&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989507.42/warc/CC-MAIN-20150728002309-00337-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 871710579,
    "recordOffset": 871699726,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Everolimus (RAD001) Drug: Placebo Interventions: Tuberous Sclerosis Complex (TSC) Lymphangioleiomyomatosis (LAM) Conditions: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Caregiver,\u00a0Investigator,\u00a0Outcomes\u00a0Assessor); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: May 23, 2012 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Everolimus \u00a0 \u00a0 Placebo \u00a0 STARTED \u00a0 \u00a0 79 \u00a0 \u00a0 39 \u00a0 COMPLETED \u00a0 \u00a0 7 [1] \u00a0 13 \u00a0 NOT COMPLETED \u00a0 \u00a0 72 \u00a0 \u00a0 26 \u00a0 Ongoing in Double-blind \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 72 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 26 \u00a0 [1] Completed means discontinued the double-blind treatment period \u00a0 Baseline Characteristics \u00a0 Show Baseline",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}